Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?

Cognition Therapeutics (NASDAQ:CGTX) stock is falling hard on Monday after the clinical-stage biopharmaceutical company provided results from its proof-of-concept Phase 2 'SHINE' study. On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. More Monday Stock Market News What's Next for CGTX Stock Thi ...